On June 29th, 2020, Sinopec Capital Co., Ltd. announced its investment in CapitalBio Technology Co., Ltd., in a bid to unleash the advantages of CapitalBio in biological chip and support the fast detection test as well as accurate prevention and control against COVID-19. 

As a core subsidiary of CapitalBio Corporation and the Biological Chip Beijing National Engineering Research Center, CapitalBio Technology serves as the industry platform which operates across the full value chain of R&D, production, marketing and the third-party, independent medical detection services. The Company is the pack leader and pioneer in biological chip industry and represents the only SOE in domestic R&D companies. During the outbreak of COVID-19 epidemic, CapitalBio was the first of this kind that developed the world’s first Respiratory Virus Nucleic Acid Detection Kit that is able to detect 6 respiratory viruses including SARS-CoV-2 within a span of 1.5 hours, together with the supply of COVID-19 Mobile Laboratory. The technology has been widely applied home and abroad. 

Mr. Huang Wensheng, Chairman of Sinope Capital said, “Sinopec has been actively responding to the Implementation Opinions on Accelerating Coronavirus Nucleic Acid Detection issued by the State Council and very much willing to unleash the advantage in epidemic control and biological chip technologies through investment. In the meantime, Sinopec Capital is committed to support independent innovation and exploration in technology front, and build a whole life-cycle and holistic health service system, so as to foster the new model of medical health service that fits Chinese national characteristics. ”

Chairman Huang Wensheng visits CapitalBio

Focusing on the five areas of new energy, new materials, energy conservation and environmental protection, advanced smart manufacturing, as well as big data and artificial intelligence, Sinopec Capital has been engaged in strategic cooperation with a number of partners since July 2018, including Xinxiang City Ruifeng New Materials Co., Ltd., Zhejiang SUPCON and Shanghai REFIRE Technology Co., Ltd.. Sinopec Capital highly values post-investment management and service and continuously empower the investees, supporting independent innovation, technology front exploration, and building a whole life-cycle and holistic health service system, so as to explore the new model of medical health service that fits Chinese national characteristics.

 COVID-19 Mobile Laboratory